Zymeworks (NASDAQ: ZYME) insider files to sell 9,560 shares after RSU vesting

Rhea-AI Filing Summary

Zymeworks Inc. insider trading notice outlines planned and recent share sales. A holder plans to sell 9,560 shares of Zymeworks common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026, with an aggregate market value of $221,505.20, while 74,836,534 shares of common stock are outstanding. These shares relate to the vesting of 17,666 restricted stock units on 01/12/2026, with vesting noted as the form of payment. The filing also reports that Paul Andrew Moore sold 20,110 shares of common stock on 01/05/2026 for gross proceeds of $504,698.65. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Zymeworks’ operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Wealth Management Canada 140 4th Ave. SW, Suite 2740 Calgary A0 T2P 3N3	9560	221505.20	74836534	01/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/12/2026	Vesting of Restricted Stock Units	Issuer			17666	01/12/2026	Vesting of Award

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Paul Andrew Moore c/o Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Common Stock	01/05/2026	20110	504698.65

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider share sale is disclosed for ZYME in this Form 144?

The notice states that 9,560 shares of Zymeworks Inc. common stock are planned to be sold through Morgan Stanley Wealth Management Canada, with an aggregate market value of $221,505.20.

How many Zymeworks (ZYME) shares are outstanding in this filing?

The filing reports that 74,836,534 shares of Zymeworks common stock are outstanding.

What recent Zymeworks (ZYME) insider sale occurred in the past three months?

The document shows that Paul Andrew Moore sold 20,110 shares of Zymeworks common stock on 01/05/2026, receiving gross proceeds of $504,698.65.

How were the Zymeworks (ZYME) shares to be sold acquired?

The 9,560 shares to be sold are tied to a vesting of restricted stock units on 01/12/2026, with the issuer listed as the source and the nature of payment described as “Vesting of Award.”

Which exchange is referenced for the Zymeworks (ZYME) shares in this Form 144?

The common stock referenced in the filing is listed on the Nasdaq exchange.

What representation does the seller make in this Zymeworks (ZYME) Form 144?

By signing, the seller represents that they do not know any material adverse information about Zymeworks’ current or prospective operations that has not been publicly disclosed.